Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | S100A4 | P26447 | 2/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | CDC25C | P30307 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | DNM2 | P50570 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.33 |
| ▸ | XDH | P47989 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | STAT1 | P42224 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401309 | 0.85 | CDC25A (0.48) | ALDH1A1APAF1S100A4CDC25ACDC25B | |
| SCHEMBL2404140 | 0.76 | CDC25A (0.66) | ALDH1A1APAF1S100A4CDC25ACDC25B | |
| SCHEMBL15698467 | 0.73 | S100A4 (0.63) | ALDH1A1APAF1S100A4CDC25BMAPT | |
| SCHEMBL9326771 | 0.73 | ALDH1A1 (0.56) | ALDH1A1APAF1S100A4MAPTGPR84 | |
| SCHEMBL458428 | 0.71 | S100A4 (0.68) | ALDH1A1APAF1S100A4CDC25BMAPT | |
| SCHEMBL3809294 | 0.70 | CDC25A (0.76) | ALDH1A1APAF1S100A4CDC25ACDC25B | |
| SCHEMBL3317054 | 0.69 | APAF1 (0.91) | ALDH1A1APAF1S100A4MAPTNPC1 | |
| SCHEMBL3315349 | 0.68 | ALDH1A1 (0.72) | ALDH1A1APAF1S100A4MAPTNPC1 | |
| SCHEMBL30587688 | 0.68 | ALDH1A1 (0.72) | ALDH1A1APAF1S100A4MAPTNPC1 | |
| SCHEMBL5925219 | 0.68 | APAF1 (0.48) | ALDH1A1APAF1S100A4CDC25ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
| EP-1325011-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002028861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | ALDH1A1 450/4885APAF1 2565/4885S100A4 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.